BRUETSCH TOBIAS (CH)
GOSSELIN FRANCIS (US)
HAN CHONG (US)
STUTZ ALFRED (CH)
WO2018109204A1 | 2018-06-21 | |||
WO2017001645A1 | 2017-01-05 | |||
WO2011036280A1 | 2011-03-31 | |||
WO2017001645A1 | 2017-01-05 | |||
WO2018109204A1 | 2018-06-21 |
EP3805231A1 | 2021-04-14 | |||
CN109265408A | 2019-01-25 | |||
US8242104B2 | 2012-08-14 | |||
US8343955B2 | 2013-01-01 | |||
US20170015678A1 | 2017-01-19 | |||
EP2017083143W | 2017-12-15 |
CAS, no. 1282512-48-4
NDUBAKU, C. O. ET AL., J. MED. CHEM., vol. 56, pages 4597 - 4610
OLIVERO AG ET AL., AACR, 2013
EDGAR K. ET AL., PRECLINICAL CHARACTERIZATION OF GDC-0077, A SPECIFIC PI3K ALPHA INHIBITOR IN EARLY CLINICAL DEVELOPMENT, no. 156
STABEN. S.: "Discovery of GDC-0077, a highly isoform selective inhibitor of PI3K alpha that promotes selective loss of mutant-pl 10alpha", AMERICAN ASSOC. FOR CANCER RES. (AACR) ANNUAL MEETING, no. DDT02-0, 2 April 2017 (2017-04-02)
"McGraw-Hill Dictionary of Chemical Terms", 1984, MCGRAW-HILL BOOK COMPANY
ELIEL, E.WILEN, S.: "Stereochemistry of Organic Compounds", 1994, JOHN WILEY & SONS
J. AM. CHEM. SOC., vol. 119, 1997, pages 9913 - 9914
ORG. PROCESS RES. DEV., vol. 18, 2014, pages 66 - 81
LOUIS F. FIESERMARY FIESER: "Reagents for Organic Synthesis", vol. 1-19, 1967, WILEY
"Beilsteins Handbuch der organischen Chemie", vol. 4, SPRINGER-VERLAG
CLAIMS 1. A compound of Formula (8A): (8A), or a salt thereof, wherein: R1 is an optionally substituted C1-12 alkyl, an optionally substituted C3-14 cycloalkyl, or an optionally substituted C6-14 aryl; and R11 is hydrogen or a hydroxyl protecting group. 2. The compound of claim 1, wherein R1 is the optionally substituted C1-12 alkyl. 3. The compound of claim 1, wherein R1 is an optionally substituted tertiary C4-12 alkyl. 4. The compound of claim 1, wherein R1 is selected from the group consisting of tert-butyl, tert-pentyl, 3-ethylpentan-3-yl, 1-methylcyclohexyl, 1-adamantyl, phenyl, and naphthyl. 5. The compound of any one of claims 1 to 4, wherein R11 is hydrogen. 6. The compound of any one of claims 1 to 4, wherein R11 is benzyl. 7. The compound of claim 1, wherein the compound is of Formula (8B): (8B), or a salt thereof, wherein: R1 is an optionally substituted C1-12 alkyl, an optionally substituted C3-14 cycloalkyl, or an optionally substituted C6-14 aryl; and R11 is hydrogen or a hydroxyl protecting group. 8. The compound of claim 1, wherein the compound is of Formula (8-1) or Formula (8-2): (8-1), or a salt thereof; or (8-2), or a salt thereof. 9. A compound of Formula (7A): (7A), or a salt thereof, wherein: R1 is an optionally substituted C1-12 alkyl, an optionally substituted C3-14 cycloalkyl, or an optionally substituted C6-14 aryl; R2 is an optionally substituted C1-12 alkyl or an optionally substituted C6-14 aryl; and each R3 is independently an optionally substituted C1-12 alkyl, an optionally substituted C6-14 aryl, or OR2. 10. The compound of claim 9, wherein the compound is of the formula (7): (7), or a salt thereof. 11. A process of preparing a compound of Formula (8C): (8C), or a salt thereof, wherein: R1 is an optionally substituted C1-12 alkyl, an optionally substituted C3-14 cycloalkyl, or an optionally substituted C6-14 aryl; the process comprising the steps of: (iii) reacting a compound of Formula (4A): (4A), or a salt thereof, wherein: R1 is an optionally substituted C1-12 alkyl, an optionally substituted C3-14 cycloalkyl, or an optionally substituted C6-14 aryl; and R4 is an optionally substituted C1-6 alkyl or hydrogen; with a Grignard reagent of formula (5A): (5A), wherein: R2 is an optionally substituted C1-12 alkyl or an optionally substituted C6-14 aryl; each R3 is independently an optionally substituted C1-12 alkyl, an optionally substituted C6-14 aryl, or OR2; and X is a halide; to thereby form a compound of Formula (7A): (7A), or a salt thereof, and (iv) reacting the compound of Formula (7A) with a fluoride salt, a base, and an oxidant to form the compound of Formula (8C). 12. The process of claim 11 further comprising the steps of: (i) partially reducing a compound of Formula (1A): (1A), or a salt thereof, wherein R4 is an optionally substituted C1-6 alkyl or hydrogen, to form a compound of Formula (2A): (2A), or a salt thereof, and (ii) reacting the compound of Formula (2A) with a sulfonamide compound of Formula (3A): (3A), wherein R1 is an optionally substituted C1-12 alkyl, an optionally substituted C3-14 cycloalkyl, or an optionally substituted C6-14 aryl, in the presence of a dehydrating reagent to form the compound of Formula (4A): (4A), or a salt thereof. 13. The process of claim 11 or claim 12, further comprising the step of: (v) reacting the compound of Formula (8C): (8C), or a salt thereof, wherein R1 is as defined in claim 11, with an acid to thereby yield an amine compound of Formula (9-1): (9-1), or an acid addition salt thereof. 14. The process of claim 13, further comprising the step of: (vi) reacting the compound of Formula (9-1), or the acid addition salt thereof, with an acylating reagent to form a compound of Formula (10-1): (10-1), or a salt thereof. 15. The process of any one of claims 11 to 14, wherein the compound of Formula (7A) is of Formula (7B): (7B), or a salt thereof, and the compound of Formula (8C) is of Formula (8D): (8D), or a salt thereof, wherein R1, R2, and R3 are as defined in claim 11. 16. The process of any one of claims 12 to 15, wherein the compound of Formula (3A) is of Formula (3B): (3B), and the compound of Formula (4A) is of Formula (4B): (4B), or a salt thereof, wherein R1 and R4 are as defined in claim 12. 17. The process of any one of claims 13 to 16, wherein the compound of Formula (9-1) is of Formula (9-3): (9-3). 18. The process of any one of claims 14 to 17, wherein the compound of Formula (10-1) is of Formula (10-2): (10-2). 19. The process of any one of claims 11 to 18, wherein R1 is tert-butyl. 20. The process of any one of claims 11 to 19, wherein R2 is 2-propyl, each R3 is methyl, and X is chloride. 21. The process of any one of claims 11 to 20, wherein R4 is ethyl. 22. The process of any one of claims 11 to 21, comprising the steps of: (iii) reacting a compound of formula (4): (4), or a salt thereof, with a compound of formula (5): (5); to form a compound of formula (7): (7), or a salt thereof; and (iv) reacting the compound of formula (7) with potassium fluoride, potassium bicarbonate, and hydrogen peroxide to form a compound of formula (8-2): (8-2). 23. The process of any one of claims 11 to 22, wherein the fluoride salt is potassium fluoride and the base is potassium bicarbonate for step (iv). 24. The process of any one of claims 13 to 23, wherein the acid for step (v) is HCl, and the acid addition salt of the compound of Formula (9-1) is a hydrochloride salt having the structure (9-2): (9-2). 25. A process of making a compound of formula (10-2) according to the following sequence of steps: . 26. A process of preparing a compound of Formula (8A): (8A), or a salt thereof, wherein: R1 is an optionally substituted C1-12 alkyl, an optionally substituted C3-14 cycloalkyl, or an optionally substituted C6-14 aryl; and R11 is a hydroxyl protecting group, the process comprising the steps of: (b) reacting a compound of Formula (12A): (12A), with a compound of Formula (13A): (13A), wherein R12 is optionally substituted C6-14 aryl and a base at a temperature below 0°C to form a compound of Formula (14A): (14A); and (c) reacting the compound of Formula (14A) with magnesium in the presence of an acetate buffer to thereby form the compound of Formula (8A). 27. The process of claim 26, further comprising the step of: (a) reacting a compound of Formula (11A): (11A), with a sulfonamide compound of Formula (3A) : (3A), in the presence of a dehydrating reagent to form the compound of Formula (12A): (12A), wherein R1 and R11 are as defined in claim 26. 28. The process of claim 26 or 27, further comprising the step of: (d) reacting the compound of Formula (8A): (8A), or a salt thereof, with an acid to yield an amine compound of Formula (9A): (9A), or an acid addition salt thereof, wherein R1 and R11 are as defined in claim 26. 29. The process of claim 28, further comprising the steps of: (e) removing the hydroxyl protecting group of the compound of Formula (9A) to form a compound of Formula (9-1): (9-1), or an acid addition salt thereof, and (f) reacting the compound of Formula (9-1), or an acid addition salt thereof, with an acylating reagent to form a compound of Formula (10-1): (10-1). 30. The process of any one of claims 26 to 29, wherein the compound of Formula (12A) is of Formula (12B): (12B), the compound of Formula (14A) is of Formula (14B): (14B), and the compound of Formula (8A) is of Formula (8B): (8B), or a salt thereof, wherein R1, R11, and R12 are as defined in claim 26. 31. The process of any one of claims 27 to 30, wherein the compound of Formula (3A) is of Formula (3B): (3B), wherein R1 is as defined in claim 27. 32. The process of any one of claims 28 to 31, wherein the compound of Formula (9A) is of Formula (9B): (9B), or a salt thereof, wherein R11 is as defined in claim 28. 33. The process of any one of claims 29 to 32, wherein the acid in step (d) is HCl and the acid addition salt of the compound of Formula (9A) or (9B) is a hydrochloride salt having the structure (9C): (9C). 34. The process of any one of claims 29 to 33, wherein the compound of Formula (9-1) is of Formula (9-3): (9-3), or the acid addition salt thereof; and the compound of Formula (10-1) is of Formula (10-2): (10-2). 35. The process of any one of claims 18-25 and 29-34, further comprising reacting a compound of Formula (10-1) or compound (10-2) having the structures: ( ), ( ), with compound 15, having the structure: , a copper salt and a ligand to form compound 16, having the structure: . 36. The process of claim 35, wherein the copper salt is copper(II) acetate or copper (I) iodide and the ligand is trans-N,N-dimethylcyclohexane-1,2-diamine. 37. The process of claim 35 or 36, further comprising reacting compound 16 with (S)-2-aminopropanoic acid and a copper (I) catalyst to form compound 17, having the structure: . 38. The process of claim 37, wherein the copper (I) catalyst is copper(I) oxide. 39. The process of claim 37 or 38, further comprising reacting compound 17 with ammonia or an ammonia equivalent and a peptide coupling reagent to form compound 18, having the structure: . 40. A process of preparing a compound of Formula (8A): (8A), or a salt thereof, wherein: R1 is an optionally substituted C1-12 alkyl, an optionally substituted C3-14 cycloalkyl, or an optionally substituted C6-14 aryl; and R11 is a hydroxyl protecting group, the process comprising the steps of: (ii) reacting a compound of Formula (4A): (4A), or a salt thereof, wherein R4 is an optionally substituted C1-6 alkyl or hydrogen; with a Grignard reagent, to thereby prepare the compound having formula (8-A). 41. The process of claim 40, wherein the Grignard reagent is prepared by reacting iodomethyl pivalate with sec-butylmagnesium chloride. 42 The process of claim 40, further comprising: (iii) hydrolyzing the compound having formula (8-A) an acid to thereby yield an amine compound of Formula (9-1): (9-1), or an acid addition salt thereof. 43. A process for preparing a compound of Formula (9-1): (9-1), or an acid addition salt thereof; the process comprising: (i) reacting a compound of Formula (2A) F F (2A), or a salt thereof; wherein R4 is an optionally substituted C1-6 alkyl or hydrogen; with (S)-2-methylpropane-2-sulfinamide to thereby prepare (S,E)-N-(2,2-difluoroethylidene)-2-methylpropane-2-sulfinamide having structure: ( ii) reacting (S,E)-N-(2,2-difluoroethylidene)-2-methylpropane-2-sulfinamide with trimethylsilyl-cyanide to give the aminonitrile (S)-N-((S)-1-cyano-2,2-difluoroethyl)-2- methylpropane-2-sulfinamide having the structure: (iii) hydrolyzing (S)-N-((S)-1-cyano-2,2-difluoroethyl)-2-methylpropane-2-sulfinamide in acid to give the product (S)-2-(chloro-λ5-azaneyl)-3,3-difluoropropanoic acid: and (iv) reducing (S)-2-(chloro-λ5-azaneyl)-3,3-difluoropropanoic acid to provide the intermediate compound of Formula (9-1) or the acid addition salt thereof. |
Scheme 1A: Alternative synthesis of Compound (10-2) by a Grignard-Tamoa Route Scheme 1A shows an alternative synthesis of (S)-4-(difluoromethyl)oxazolidin-2-one (10-2). Further details of process are provided in the Examples below. Scheme 2: Synthesis of Compound 10-2 by a Grignard-Knochel Route 8-3 9-3 10-2 (i) Ti(OEt) 4 , neat, 60°C, 42% o. th., (ii) iodomethyl pivalate, iPrMgCl, THF/NMP, -65°C, 75% o. th.; (iii) HCl, 22%, 80°C, 2 hours, 97%, o. th.; and (iv) Et 3 N, CDI, ACN, r.t., 55%, o.th. Scheme 2 shows the synthesis of intermediate 9-3. Magnesation of iodomethyl pivalate was done according to the protocol reported by Knochel at -78°C (Synlett, (11), 1820-1822; 1999).2.2 equivalent of iodomethyl pivalate and isopropylmagnesium chloride was used in order to eliminated ethanol from N,O-acetal 4 to generate the imine in-situ, which reacts further to 8-3. The reaction worked very well on small scale and 8-3 was isolated 75% o. th. after purification by column chromatography. No minor isomer could be detected (crude 1 H-NMR). The reaction was repeated on 20 g scale. In this case, gummy balls were formed after magnesation of iodomethyl pivalate at -60 to 78°C. Knochel describes the Grignard reagent to be stable for only few hours. Ester 8-3 was hydrolyzed using HCl at 80°C to obtain aminoalcohol hydrochloride 9-3 in quantitative yield. Amino alcohol hydrochloride 9-3 was mixed with triethylamine and ACN at room temperature. CDI was added at room temperature in one portion. Full conversion of 9-3 was obtained after 2 h. The volatiles were evaporated and the crude product was purified by column chromatography. (S)-4-(difluoromethyl)oxazolidin-2-one (10-2) was obtained as pale yellow oil (308 mg, 55% o. th., single enantiomer). Scheme 3: Synthesis of Compound (10-2) by a Strecker Route (i) (S)-Ellmans aux, toluene reflux 18% o. th.; (ii) TMSCN (2.0 eq), cat. Y(OTf 3 ), 10 V DCM, rt, 73% o. th., dr = 5:1, isol. dr =89:11; (iii) HCl, 33%, 80°C; (iv) BH3, THF, 0 - 45°C, 30% o. th.; and (v) Et 3 N, CDI, IPAc, rt, 45-50% o. th. Scheme 3 shows the synthesis of (S)-4-(difluoromethyl)oxazolidin-2-one (10-2). Hemiacetal 2 and (S)-tertbutylsulfinamide in toluene was refluxed under Dean-Stark conditions. The desired imine was obtained by vacuum distillation in low yield. Severe corrosion on our laboratory glass equipment was observed. This indicates hydrofluoric acid formation due to decomposition. Strecker reaction of the (S)-tertbutylsulfinamide using TMS-CN and Lewis acid gave the desired aminonitrile. Diastereoselectivity of the Strecker reaction was found to depend strongly depends on the Lewis (scandium triflate, Yttrium triflate and trimethylsilyl triflate). Reaction was performed on larger scale using yttrium triflate. The crude product was purified by column chromatography to obtain the aminonitrile in 73% o. th. and dr of 89:11. Aminonitrile was hydrolyzed and auxiliary was cleaved using aq. HCl to obtain alanine hydrochloride derivative 9-2. Reduction of carboxylic acid 9-2 using borane THF complex led to aminoalcohol 9-3 in low yield. The sequence was completed using CDI to obtain oxazolidinone 10-2. Based on chiral GC analysis we obtained the enantiomer of 10-2 with de of 89:11. Scheme 4: Synthesis of Compound (10-2) by a Sulfone Route (a) CuSO4, DCM; (b) NaHMDS, THF, -78°C, quant yield d.r. > 99:1 (NMR); (c) Mg, AcOH/NaOAc, DMF, rt 48% o. th.; (d) HCl, 37%, MeOH, rt, 79% o. th.; (e) H2, Pd/C, MeOH, rt, 78% o. th.; and (f) DIPEA, CDI, THF, rt, 44% o. th. Scheme 4 shows the synthesis of (S)-4-(difluoromethyl)oxazolidin-2-one (10-2). Aldehyde 2-(benzyloxy)acetaldehyde 11 and (S)-tertbutylsulfinamide 3 were stirred in the presence of copper sulfate in dichloromethane (DCM). Full and clean conversion to imine (R,E)- N-(2-(benzyloxy)ethylidene)-2-methylpropane-2-sulfinamide 12 was obtained overnight. Running the reaction at reflux in toluene led to severe drop of yield (< 50% o. th.). Imine 12 and difluoromethyl phenyl sulfone 13 were treated with sodium bis(trimethylsilyl)amide (NaHMDS) at -70°C as a solution in tetrahydrofuran (THF) to obtain the desired product 14. The reaction profile was very clean (TLC only one spot) and no minor diastereomer was detected by NMR. Phenylsulfone (R)-N-((S)-3-(benzyloxy)-1,1-difluoro-1-(phenylsulfonyl)prop an-2-yl)-2- methylpropane-2-sulfinamide 14 was deprotected using elemental magnesium turnings in dimethylformamide (DMF)/acetate buffer to obtain key intermediate (S)-N-((S)-3-(benzyloxy)- 1,1-difluoropropan-2-yl)-2-methylpropane-2-sulfinamide 8-1 as the single product in 48% o. th. (not optimized). Alternative methods to remove the sulfone such as hydrogenation by Raney nickel didn't give any conversion to 8-1. The auxiliary was cleaved using aq. HCl in methanol to obtain the ammonium hydrochloride of 3-(benzyloxy)-1,1-difluoropropan-2-amine 9-5 in good yield as a white crystalline solid. Benzyl group of 9-5 was removed by hydrogenation with Pd/C to obtain the ammonium hydrochloride of 2-amino-3,3-difluoropropan-1-ol 9-2 as a white solid. (S)-4-(difluoromethyl)oxazolidin-2-one (10-2) was obtained in moderate yield by treating 9-2 with N,N-diisopropylethylamine (DIPEA) to release the free amine followed by addition of carbonyl diimidazole (CDI). Based on chiral GC analysis we obtained the enantiomer of (S)-4- (difluoromethyl)oxazolidin-2-one (10-2) with > 99.9% ee. Scheme 5: Synthesis of Compound 18 a: i) Mg(OEt) 2 , MeOH, MeTHF, ii) HCl, n-PrOH; b: ClCHCHO, KHCO 3 , MeTHF, H 2 O, c: NIS, DMF; d: EtMgBr, THF; e: (10-2), Cu(OAc) 2 , trans-N,N’-dimethylcyclohexane-1,2- diamine, Cs 2 CO 3 , MeTHF; f: i) (S)-2-aminopropanoic acid, Cu 2 O, K 3 PO 4 , DMSO, ii) NH 3 , MeOH, THF; g: i) NH 3 , HOSu, EDC, THF, i PrOH, ii) EtOH, H 2 O. Scheme 5 shows the preparation of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3- yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amin o)propanamide 18. 2-(5-Bromo-2- cyanophenoxy)ethan-1-aminium chloride 11′ cyclized with magnesium ethoxide, Mg(OEt) 2 in methanol, and acidification with a solution of hydrogen chloride in n-propanol to give of 8- bromo-2,3-dihydrobenzo[f][1,4]oxazepin-5-amine hydrochloride 12′. Cyclization of 12′ to form the imidazole ring with aqueous chloroacetaldehyde in the presence of potassium bicarbonate as base gave 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine 13′. Bis-iodination of the imidazole 13′ with N-iodosuccinimide (NIS) or other iodinating reagents such as iodine or iodine monochloride gave 9-bromo-2,3-diiodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxa zepine 14′. Selective reduction of 14′ via an iodo-metal exchange using a Grignard reagent such as ethylmagnesium bromide or isopropylmagnesium chloride gave 9-bromo-2-iodo-5,6- dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine 15. Chemoselective replacement of iodide from 15 with (S)-4-(difluoromethyl)oxazolidin-2-one (10-2) in the presence of a copper catalyst such as copper (II) acetate or copper (I) iodide, a ligand such as trans-N,N’-dimethylcyclohexane-1,2- diamine,1,10-phenanthroline, or 3,4,7,8-tetramethyl-1,10-phenanthroline, an inorganic base such as cesium carbonate or tripotassium phosphate, and 2-methyltetrahydrofuran or acetonitrile as the solvent gave (S)-3-(9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepi n-2-yl)-4- (difluoromethyl)oxazolidin-2-one 16. Replacement of bromide from 16 with (S)-2- aminopropanoic acid in the presence of a copper catalyst such as copper (I) oxide, an inorganic base such as tripotassium phosphate, and DMSO as the solvent followed by the ammonium salt formation in THF using a solution of ammonia in methanol as the ammonia source gave ammonium (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6- dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propio nate 17. Conversion of the carboxylate salt 17 to the carboxamide was effected with a solution of ammonia in 2-propanol, an additive such as N-hydroxysuccinimide (HOSu) or 1-hydroxybenzotriazole (HOBt), and a dehydrating reagent such as N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC) or N,N'-diisopropylcarbodiimide (DIC) in THF to give 18. EXAMPLES Scheme 1 Scheme 1 Step (i): Hemiacetal, 1-ethoxy-2,2-difluoroethan-1-ol 2 was obtained by partial reduction of ethyl 2,2-difluoroacetate 1 using sodium bis(2-methoxyethoxy)aluminium hydride (Red-Al) at 0°C. Hemiacetal, 1-ethoxy-2,2-difluoroethan-1-ol 2 was obtained in a solution in tert-butyl methyl ether TBME. Scheme 1 Step (ii): Difluoroacetaldehyde ethyl hemiacetal 2 (60.7 g; 90% w/w:10% w/w ethanol) was placed in a 500 mL double glass jacked reactor equipped with a mechanical stirrer, thermometer, funnel, and nitrogen supply. (S)-tert-Butylsulfinamide 3 (50.0 g) and Titanium(IV)ethoxide (99.0 g) were added at a temperature less than 20°C. The suspension was heated to 80-90°C for at least 3 hours. The reaction mixture was stirred at this temperature for 4 hours until an orange solution is formed. This solution was cooled to 70-80°C, and the amount of (S)-tert-Butylsulfinamide 3 was determined. The reaction mixture was cooled to 15-25°C and aged for at least 2 hours. In a separate 100 mL double glass jacked reactor equipped with a mechanical stirrer, thermometer, funnel, and nitrogen supply was added 200 mL pharmaceutical grade water and citric acid (79.4 g) at a temperature of 50°C. Potassium hydroxide (58.9 g, 50%) was added and the temperature was lowered to 15-20°C. The reaction mixture (204 g, 190 mL) prepared above was added adiabatically at a temperature less than 45°C. The orange solution was stirred for at least 60 minutes at a temperature between 30-40°C. The phases are separated into aqueous and organic phases. tert-Butylmethylether was added to the aqueous phase, and the mixture was stirred for at least 5 minutes at 30-40°C, which was followed by another phase separation. The two organic phases are combined at a temperature less than 30°C. Pharmaceutical grade toluene (100 mL) was added, and the mixture was stirred for at least 5 minutes at a temperature between 15-25°C. The phases are separated for at least 10 minutes. Magnesium sulfate (anhydrous, 35 g) was suspended in pharmaceutical grade toluene (80 mL), added to the organic phase, and stirred for at least 30 minutes at a temperature less than 30°C. The suspension is filtered. The filtrate contains the desired product (443 mL; 398 g). The filtrate is heated to a temperature between 35-45°C and distilled at reduce pressure (90-22- mBar) to collect the Distillate 1 (312 mL, 253 g). Distillation is continued by additions of pharmaceutical grade toluene (150 mL) to collect Distillate 2 (160 mL, 136 g). (S)-N-(1-ethoxy- 2,2-difluoroethyl)-2-methylpropane-2-sulfinamide 4 (170 mL, 171.2 g) was obtained as a pale yellow solution in toluene by filtering the combined distillates with pharmaceutical grade toluene (50 mL). The yield was 89.2% with a purity of 98.1%. Scheme 1 Step (iii): Tetrahydrofuran (stabilized, 700 mL) was placed in a 1500 ml double glass jacked reactor equipped with a mechanical stirrer, a thermometer, addition funnel and nitrogen supply at less than 30°C. Magnesium turnings (23.9 g) were added at less than 30°C. The suspension was warmed to 55-65°C. 1,2-dibromoethane (6.4 g) was added over 15 minutes, keeping the temperature between 55-65°C. (Chloromethyl)dimethyl isopropyloxysilane (5.7 g) was added over at least 20 minutes keeping the temperature between 55-65°C . The suspension was stirred for at least 15 minutes. (Chloromethyl)dimethyl isopropyloxysilane (164.0 g) was added over at least 120 minutes keeping the temperature between 55-65°C. The black mixture was stirred for at least 60 minutes a temperature between 55-65°C and then cooled to between 45-55°C. The mixture was cooled to 0-10°C. ((isopropoxydimethylsilyl)methyl)magnesium chloride 5 was obtained in solution at a purity between 85-90%. (S)-N-(1-ethoxy-2,2-difluoroethyl)-2- methylpropane-2-sulfinamide 4 (160 g) in toluene was added over a period of 2 hours. A solution was prepared by combining pharmaceutical grade water (168 g), citric acid (117.3 g) and ammonia solution (122.4 g, 25%) and mixing at a temperature between 15-20°C. The mixture (1050 mL) of ((isopropoxydimethylsilyl)methyl)magnesium chloride 5 and (S)-N-(1- ethoxy-2,2-difluoroethyl)-2-methylpropane-2-sulfinamide 4 was added to the ammonium citrate solution over 5 minutes. The biphasic mixture was stirred at a temperature between 35-45°C for at least 10 minutes, and the phases were separated for at least 15 minutes. The lower, aqueous phase (350 mL, 438 g) was drained, leaving a light brown, clear organic phase (1050 mL, 940 g). Potassium hydrogen carbonate (1.7 g) and pharmaceutical grade water (34 mL) was added to the organic phase. The organic phase was distilled at temperature between 35-50°C at reduced pressure (90-300 mBar). The collected distillate (420-450 mL) was combined with pharmaceutical grade water (600 mL) and distilled again until between 1000-1050 mL distillate was collected. The distillate contained (S)-N-((R)-1,1-difluoro-3- (isopropoxydimethylsilyl)propan-2-yl)-2-methylpropane-2-sulf inamide 7 (887 g). The pH of the distillate was adjusted to between pH 5.2-5.7 using citric acid (10% solution) and distilled again at a temperature between 35-55°C and reduced pressure between 80-120 mBar to collect 480-520 mL distillate. This distillate contained 492 g of (S)-N-((R)-1,1-difluoro-3- (isopropoxydimethylsilyl)propan-2-yl)-2-methylpropane-2-sulf inamide 7. Scheme 1 Step (iv): The distillate (196 g) of step (iii) containing (S)-N-((R)-1,1-difluoro-3- (isopropoxydimethylsilyl)propan-2-yl)-2-methylpropane-2-sulf inamide 7 was placed in a 1000 mL double glass jacked reactor equipped with a mechanical stirrer, thermometer, funnel, and nitrogen supply. The distillate was heated to between 40-50°C and potassium hydrogen carbonate (33.9 g), potassium fluoride (39.4 g), and tertbutylammonium hydrogen sulfate (5.9 g) were added. Hydrogen peroxide (49.58 g 35%) was dosed over at least 180 minutes. The pale yellow emulsion was aged for at least 30 minutes at a temperature between 40-55°C. The biphasic mixture was cooled to 15-25°C, and sodium sulfite (4.27 g) was added over 30 minutes at temperature between 15-30°C. The reaction vessel was flushed with nitrogen to purge oxygen, and anhydrous acetonitrile (150 mL) was added with Celite 545 AW (15 g). The suspension was stirred for at least 30 minutes. The suspension was filtered. The filtrate was washed with anhydrous acetonitrile twice (35 mL). The resulting triphasic mixture was allowed to separate for at least 15 minutes at 20-30°C. The lowest aqueous phase was drained, and the biphasic mixture was allowed to separate for 15 minutes. The oily middle phase was drained. The upper organic phase (290 mL, 271 g) was distilled at 40-50°C and reduced pressure between 90-240 mBar. Toluene (300 mL) was added during distillation. The collected distillate was 390 mL, weighing 324 g. Anhydrous acetonitrile (40 mL) was added to the distillate, and the mixture was warmed to 60-70°C. Product crystallized upon cooling to 35-40°C. The solution was filtered, and the solids rinsed with anhydrous acetonitrile. Toluene (100 mL) was added, and the mixture was distilled at 40-50°C at reduced pressure of 120-240 mBar. The collected distillate was 90-110 mL, weighing 127 g. Toluene (50 mL) was added and distillation continued. The distillate was cooled to 0-10°C over at least 120 minutes. The distillate was filtered. The solid filter cake was washed with toluene twice (50 mL, 25 mL), and crude (S)-N-((S)-1,1-difluoro-3-hydroxypropan-2-yl)-2-methylpropan e-2- sulfinamide 8-2 (49.06 g) was obtained and dried at 40-50°C at 20 mBar. Pure (S)-N-((S)-1,1- difluoro-3-hydroxypropan-2-yl)-2-methylpropane-2-sulfinamide 8-2 (46.0 g) was obtained at 63% yield. 1 H NMR (400 MHz, DMSO-d 6 ) δ 6.04 (td, J = 55.6, 3.3 Hz, 1H), 5.53 (d, J = 9.1 Hz, 1H), 4.96 (s, 1H), 3.54(dd, J = 6.3, 3.6 Hz, 2H), 3.43 (ddqd, J = 18.6, 9.4, 6.0, 3.0 Hz, 1H). 13 C NMR (101 MHz, DMSO-d 6 ) δ 115.90 (t, J = 242.5 Hz), 60.44, 59.02 (t, J = 20.5 Hz), 56.34, 22.86. Scheme 1 Step (v): 1-Propanol (32.7 g) was placed in a 200 ml double glass jacked reactor equipped with a mechanical stirrer, a thermometer, addition funnel and nitrogen supply at less than 20°C. Hydrochloric acid (gas, 9.0 g) was charged at less than 20°C below solvent niveau. Dry (S)-N- ((S)-1,1-difluoro-3-hydroxypropan-2-yl)-2-methylpropane-2-su lfinamide 8-2 (45.0 g) was added in portions over 90 minutes, and the suspension was stirred for 30 minutes at 15-25°C. Crystallization spontaneously occurred. Toluene (20 mL) was added over 30 minutes, and the suspension was stirred for at least 30 minutes. The suspension was filtered. The filter cake was washed three times with toluene (total of 60 mL). The hydrochloride salt of (S)-N-((S)-1,1-difluoro-3-hydroxypropan- 2-yl)-2-methylpropane-2-sulfinamide 9-2 was obtained at a mass of 31.6 g, which was then dried under vacuum (20 mBar) at 45°C. Dry hydrochloride salt of (S)-N-((S)-1,1-difluoro-3- hydroxypropan-2-yl)-2-methylpropane-2-sulfinamide 9-2 was obtained at a mass of 29.5G, with 99.7% purity and 96% yield. 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.78 (s, 3H), 6.31 (td, J = 54.3, 3.9 Hz, 1H), 5.63 (s, 1H), 3.88 – 3.66 (m, 2H), 3.57 (ddq, J = 14.6, 9.4, 4.8 Hz, 1H). 13C NMR (101 MHz, DMSO-d 6 ) δ 114.20 (t, J = 238.9Hz), 63.56 (t, J = 4.6 Hz), 53.2 (dd, J = 24.2, 23.6 Hz). Scheme 1 Step (vi): 2,2,2-Trifluoroethanol (850 g) was placed in a 3500 ml double glass jacked reactor quipped with a mechanical stirrer, a thermometer, addition funnel and nitrogen supply at less than 30°C. 1,1'-Carbonyldiimidazole (652 g) was dosed in portions at temperature between 10- 35°C over at least 60 minutes. The light brown suspension was warmed up to between 80-140°C (start: 90°C, end: 130°C) and distillation was performed at 200-270 mbar.919 g, 620 ml distillate 1 is collected. The distillate was cooled to 80-100°C, and pharmaceutical grade water (15 g) was added over 60 minutes, followed by another 480 g over 15 minutes, followed by cooling the distillate to less than 30°C. The solution is Distillate 1. 2,2,2-Trifluoroethanol (911 g) was placed in a 3500 ml double glass jacked reactor quipped with a mechanical stirrer, a thermometer, addition funnel and nitrogen supply at less than 30°C. Dry hydrochloride salt of (S)-N-((S)-1,1-difluoro-3-hydroxypropan-2-yl)-2- methylpropane-2-sulfinamide 9-2 (330 g) was added, and the suspension was warmed to 40-55°C. Potassium carbonate (401 g) was added over 30 minutes, and the addition funnel was rinsed with 2,2,2-Trifluoroethanol (137 g). Distillate 1 (833 g) was added over 60 minutes at 40-55°C, followed by stirring for at least 60 minutes. The suspension was cooled to 15-25°C and pharmaceutical grade water (990 g), hydrochloric acid (382 g, 33%) was added, and the pH was adjusted to between 5.8 to 6.2 with additional hydrochloric acid. The suspension was warmed to 40-55°C and distilled at 220-270 mBar. 1400-1600 mL of distillate was collected. The solution was cooled to 15-30°C (target: 25°C), and the pH was adjusted with hydrochloride acid. Water (150 g) and Isopropyl acetate (990 mL) were added and the biphasic colorless mixture was stirred for at least 15 minutes. Phases were separated for at least 5 minutes. The aqueous phase was extracted eleven times with Isopropyl acetate (each 330 ml) at 15-30°C. The mixture was stirred for at least 15 minutes for each extraction. Phases were separated for at least 5 minutes. Pure water (20 mL) was added when salt is precipitating. All organic extracts (4442 g, 4940 mL) were collected and combined. The organic layer was distilled at 35-55°C and pressure between 170-250 mBar. The distillate was filtered and washed with isopropyl acetate (200 mL). Seed crystals (100 mg) were added, if needed. The suspension was cooled to 0 to 10°C, and methyl cyclohexane (1815 mL) was added over 60 minutes. The suspension was aged for at least 30 minutes, followed by filtering twice with methyl cyclohexane (660 mL total). Wet (S)-4-(difluoromethyl)oxazolidin-2-one 10-2 (291 g) was dried at 25-35°C and 10 mBar pressure. The dried product was 283 g, with a purity near 100% and 92% yield. 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.26 (s, 1H), 6.09 (td, J = 55.3, 3.3 Hz, 1H), 4.41 (tt, J = 9.3, 1.1 Hz, 1H), 4.25 (dd, J = 9.3, 4.2 Hz, 1H), 4.22 – 4.08 (m, 1H). 13 C NMR (101 MHz, DMSO-d 6 ) δ 159.07, 115.45 (t, J = 251.5 Hz), 63.56 (t, J = 4.7 Hz), 53.2 (t, J = 24.3 Hz). Scheme 1A Scheme 1A Step 1: Difluoroacetaldehyde-ethylhemiacetal (72.8 kg, 1.05 eq), Ethanol (2 kg) and (S)-tert- butylsulfinamide (60.0 kg, 1.0 eq) were charged and the temperature was set to ≤ 25°C. Titanium(IV)ethoxide (119 kg, 1.0 eq) ad Ethanol (5 kg) was added and the temperature was increased to 80-90°C over a period of at least 90 minutes. The reaction mixture was stirred for at least 4 h at 80-90°C and the conversion was checked by LC. When the IPC limit was fulfilled ((S)-tertbutylsulfinamide ≤ 1.0%-a/a), the reaction mixture was cooled to 15-25°C and aged for at least two hours. Disappearance of hydrate impurity was checked by LC. When the IPC limit was fulfilled (hydrate step 1 ≤ 1.0%-a/a), the reaction mixture was quenched under adiabatic conditions on potassium citrate solution (95 kg, 1.0 eq citric acid; 71 kg, 1.27 eq KOH 50%; 240 kg water) at 30-40°C. The reactor vessel was rinsed with TBME (60 L). The quenched mixture was stirred for 60 minutes and the phases were separated. The upper organic phase was kept in a separate vessel and the lower aqueous phase was extracted once with TBME (60 L). The lower aqueous phase was drained and the two organic phases were combined. Toluene (120 L) was added to the combined organic phase and the mixture was stirred for 15 minutes. The newly formed aqueous layer was separated for 15 minutes and drained. Magnesium sulfate (42 kg, 0.71 eq) was added as suspension in toluene (72 L). Residual water was controlled by Karl-Fischer titration. When the IPC limit was fulfilled (water ≤ 2.0%-w/w), the suspension was filtered off and the filter cake was washed with toluene (2 x 36 L). Solvents were partially distilled off under reduced pressure at 30-45°C. Feed distillation with toluene (180 L) was performed to remove ethanol. Content of ethanol was checked by GC-HS (Ethanol ≤ 1.0%-w/w). Step 1 solution was diluted with toluene (60 L) and discharged over a filter cartridge and directly telescoped into the subsequent step. Scheme 1A Step 2: Magnesium turnings (9.8 kg, 2.9 eq) and THF (255 kg) were charged and the suspension was warmed up to 50-65°C.1,2-Dibromoethane (0.8 kg, 0.1 eq) was added and the mixture was stirred for at least 10 minutes while ethylene gas was formed. (Chloromethyl)dimethyl isopropyloxy silane (3.6 kg, 0.1 eq) was added over at least 20 minutes at 50-65°C (target: 60°C). Initiation of the reaction was checked by observation of heat formation. In case the increase of temperature is not clearly noticeable, the initiation of the reaction can be checked by GC ((chloromethyl)dimethyl isopropyloxy silane ≤ 5.0%-a/a). When the IPC limit was fulfilled (increase if internal temperature ≥ 3°C or conversion), dosage of the remaining (chloromethyl)dimethyl isopropyloxy silane (4 x 16.5 kg, 2.9 eq) was completed over at least four hours. The reaction mixture was aged for at least 60 minutes at 50-65°C. Complete consumption of magnesium turnings was checked by GC ((chloromethyl)dimethyl isopropyloxy silane ≥ 3.0%- a/a). If the IPC criteria is reached, the reaction mixture is cooled down to 0-10°C. The step 1 solution in toluene (74 kg, 1.0 eq) was added over at least 120 minutes at 0-10°C. An informative IPC was measured to check the reaction profile. In a second reactor the ammoniumcitrate solution was prepared and precooled to 10-20°C (48 kg, 1.8 eq citric acid; 50 kg, 5.3 eq ammonia 25%; 69 kg water). The reaction mixture from the first reactor was poured under adiabatic conditions on the ammoniumcitrate solution. The temperature of the the quench mixture reaches 34-45°C. THF was added (10 L). The lower aqueous layer was separated and drained. A solution of potassium hydrogen carbonate 5% (0.7 kg, 0.05 eq) in water (14 kg) was added. Most of the solvent was removed at 35-45°C and 100-250 mbar followed by a feed distillation with water (250 kg) to remove THF and volatile siloxane residues. Removal of THF was checked by GC-HS (THF ≤ 0.50%-w/w). A solution of citric acid (10 L, 10% in water) was added to adjust the pH to 5.5 at 35-45°C. The distillation was continued at 40-55°C and 50-150 mbar to remove isopropanol/water. Conversion of step 2 intermediate and removal of solvents was checked by LC and GC-HS (THF ≤ 0.50%-w/w, isopropanol ≤ 0.50%-w/w, step 2 intermediate ≤ 10%-a/a). If the IPC criteria is fullfilled the mixture is discharged over a filter cartridge to obtain step 2 as biphasic mixture with water. This mixture was directly telescoped into the subsequent step. Scheme 1A Step 3: Step 2 (12.14 kg, 1.0 eq) as biphasic mixture with water was charged together with potassium hydrogen carbonate (2.17 kg, 1.0 eq), potassium fluoride (2.52 kg, 2.0 eq) and tetrabutylammonium hydrogen sulfate (0.37 kg, 0.05 eq). The mixture was warmed up to 40-50°C and hydrogen peroxide 35% (3.16 kg, 1.5 eq) was added over at least 180 minutes. The mixture was aged for at least 60 minutes. The conversion was checked with LC. When the IPC limit was fulfilled (step 2 and step 2 dimer < 5.0%-a/a), the reaction mixture was quenched with sodium sulfite (0.27 kg, 0.1 eq) at 40-50°C. The mixture was diluted with toluene (7.8 kg, 0.7 V) at 40- 50°C. The biphasic turbid emulsion was cooled down to 35-45°C (target: 40°C) and the mixture was aged for at least 60 minutes to initiate the crystallization spontaneously. The suspension was cooled to 0-10°C over at least 180 min and stirred for at least 30 minutes. The product was isolated by filtration and the filter cake was washed with toluene (10 L, 0.6 V). Step 3, crude, wet was dried at 40-50°C under reduced pressure until the water content was < 1.0%-w/w. Step 3, crude, dry was obtained as off-white to orange solid with off-white inorganic salts (4.75 kg, 56% o. th., 99.2%-a/a and 62%-w/w). Scheme 1A Step 4: Step 3 crude dry (4.75 kg, 1.0 eq, 62%-w/w) mixture with salts, acetonitrile (11.7 kg, 2.8 V) and toluene (1.3 kg, 0.27 V) were charged, and the mixture was warmed up to 40-50°C. The suspension was filtered to a second reactor and the filter cake was washed with acetonitrile (3.9 kg, 0.53 V). The solution was concentrated at 40- 50°C under reduced pressure (2 V distillate). The distillation was continued at 40-50°C under reduced pressure by feeding toluene (15.5 kg, 3.3 V) at a constant reactor level while a suspension was formed. The suspension was cooled down to 15-25°C and 1-propanol (2.47 kg, 3.0 eq) was added. Hydrogen chloride gas (0.55 kg, 1.1 eq.) was passed in at 15-25°C over at least 1 h and the suspension was aged for at least 30 minutes. The conversion was checked with GC. When the IPC limit was fulfilled (step 3 ^ 0.5%-a/a), the product was isolated by filtration and the filter cake was washed with toluene (5.7 kg, 1.2 V displacement). Step 4, pure, wet was dried at 40-50°C under reduced pressure until LOD < 0.40%-w/w and 1- propanol < 500 ppm was reached. Step 4, pure, dry was obtained as white to off-white solid (1.88 kg, 94% o. t. and 99.9%-a/a purity). Scheme 1A Step 5: The reagent (bis(2,2,2-trifluoroethyl) carbonate was prepared according to the following procedure: 2,2,2-Trifluoroethanol (104 kg, 2.1 eq) was charged at JT ≤ 30°C.1,1'- Carbonyldiimidazole (80 kg, 1.0 eq) was dosed in portions over at least 60 minutes at IT = 10- 55°C. The thick suspension was heated up to IT = 80- 130°C and bis(2,2,2-trifluoroethyl) carbonate (BTFEC) was distilled off under reduced pressure (150- 300 mbar). The purity of BTFEC in the distillate was checked by GC (typically 90-93%-a/a). The distillation residue was quenched by a small portion of water (1.8 kg, 1.8 L). Complete hydrolysis of the remaining bis(2,2,2-trifluoroethyl) carbonate in the distillation residue was controlled by GC (IPC bis(2,2,2- trifluoroethyl) carbonate ≤ 0.1%-a/a). When the IPC criterial was fulfilled, the quenched residue was diluted with water (57 kg, 57 L) and disposed. The process for the oxazolidinone formation was performed according to the following procedure: Step 4, pure dry (15.0 kg, 1.0 eq) was suspended in 2,2,2-trifluoroethanol (45 kg, 32 L) at IT ≤ 30°C. The suspension was warmed up to IT = 40-55°C. Potassium carbonate powder (18.2 kg, 1.3 eq) was added in portions over at least 30 minutes at IT = 40-55°C. The addition funnel was rinsed with a small amount of 2,2,2-trifluoroethanol (2 L). Bis(2,2,2-trifluoroethyl) carbonate (34.4 kg, 1.5 eq) was dosed over at least 60 minutes at IT = 40-55°C. The suspension was additionally aged for at least 60 minutes. Conversion was checked by GC (Step 4 ≤ 0.5%-a/a). When the IPC limit was fulfilled, the mixture was cooled down to IT = 15-30°C and the reaction mixture quenched by the addition of water (44 kg, 44 L) at IT ≤ 30°C. The pH was adjusted to 5.5-6.5 with hydrochloric acid 33% (19.4 kg, ~1.6 eq). A fraction of solvent was distilled off at IT = 40-55°C under reduced pressure. The mixture was cooled down to IT = 15-30°C and the pH was checked and readjusted to 5.5-6.5 with a small amount of hydrochloric acid 33%. The aqueous product solution was extracted twelve times with isopropyl acetate (170 kg, 195 L). The combined organic layers were concentrated at IT = 40-55°C under reduced pressure. The concentrate was transferred to a second reactor over a filter cartridge. The filter cartridge was rinsed with a small amount of isopropyl acetate (8 L). The product was further concentrated at IT = 40-55°C under reduced pressure. The product solution was cooled down to IT = 35-40°C. The mixture was seeded if the crystallization has not initiated spontaneously. Initiation of the crystallization was controlled by visual inspection. After the crystallization has been initiated, the suspension was cooled down to IT 0-10°C over a period of at least 120 minutes. Then, methyl cyclohexane (69 kg, 89 L) was added over a period of at least 60 minutes. The suspension was aged for at least 30 minutes to complete the crystallization process. The product was isolated by centrifugation. The pure, wet was dried at 25-35°C under reduced pressure to afford the pure, dry as a white to off-white solid (23.4 kg, 89% o. th., 100%-a/a purity). Scheme 2 Scheme 2 Step (i): (i) Ti(OEt) 4 , neat, 60°C, 42% o. th. (S)-tert-Butylsulfinamide 2 (10 g, 82 mmol, 1.0 eq), hemiacetal 3 (14.8 g, 116 mmol, 1.4 eq) and titanium ethoxide (26.3 g, 116 mmol, 1.4 eq) were mixed and heated to 60°C. Full conversion of 3 was obtained after 16 h (TLC). The solution was quenched on saturated brine (50 ml) and EtOAc (200 ml). The slurry was filtered over Celite (10 g). The phases were separated and the organic layer was dried over MgSO 4 . The solvent was evaporated and the crude product was purified by column chromatography (EtOAc Cyclohexane 2:1). N,O-Acetal 4 was obtained as colorless solid (7.2 g, 42% o. th.). 1 H NMR (300 MHz, DMSO-d 6 ) δ 6.45 (d, J = 10.0 Hz, 1H), 5.83 (td, J = 55.4, 4.4 Hz, 1H), 4.65 – 4.41 (m, 1H), 3.88 (dq, J = 9.5, 7.1 Hz, 1H), 3.50 (dq, J = 9.5, 6.9 Hz, 1H), 1.17– 1.10 (m, 12H tBu). Scheme 2 Step (ii): Iodomethyl pivalate (8.0 g, 33 mmol, 3.0 eq) was dissolved in a mixture of THF (50 ml) and NMP (10 ml). The solution was cooled down to -65°C. iPrMgCl 2.0 M solution in THF (19.0 ml, 38 mmol, 3.5 eq) was added at IT = -65°C over 30 min. Subsequently, the N,O-acetal 4 (2.5 g, 11 mmol, 1.0 eq) dissolved in THF (5 ml) was added over 30 min at - 65°C. The diastereoselectivity was 94:6 (NMR). The mixture was quenched on saturated aquouse NH 4 Cl solution (50 ml). The aquouse layer was extracted with TBME. The organic layers were combined and dried over MgSO4. The crude product was purifed by column chromatography to give pivalate 8-3 as greazy solid (2.46 g, 75% o. th.). 1 H NMR (300 MHz, DMSO-d 6 ) δ 6.09 (td, J = 55.1, 3.6 Hz, 1H), 5.81 (d, J = 9.3 Hz, 1H), 4.18 (dd, J = 11.5, 5.1 Hz, 1H), 4.08 (ddd, J = 11.5, 6.4, 1.1 Hz, 1H), 3.88 – 3.62 (m, 1H), 1.15 (s, 9H), 1.14 (s, 9H). Scheme 2 Step (iii): Pivalate 8-3 (1.0 g, 4.4 mmol, 1.0 eq) was mixed in HCl 33% (4 ml). The reaction mixture was heated to 80°C. Full conversion of pivalate 8-3 was obtained after 2 h (TLC: EtOAc). The mixture was concentrated and co-evaporated with MeOH, ACN and toluene. The remaining solid was suspended in TBME (5 ml) and filtered off. The amino alcohol hydrochloride 9-3 was obtained as greazy solid (0.64 g, 97% o. th. 1 H NMR (300 MHz, DMSO-d 6 ) δ 8.78 (s, 3H), 6.31 (td, 1H, J = 54.3 Hz, J = 3.9 Hz, H3), 5.63 (s, 1H, OH), 3.88 – 3.66 (m, 2H, H1), 3.65-3.50 (m, 1H, H2). Scheme 2 Step (iv): The amino alcohol hydrochloride 9-3 (0.60 g, 4.1 mmol, 1.0 eq) was mixed with triethylamine (1.2 ml, 8.2 mmol, 2.0 eq) and ACN (5 ml, 8 V) at room temperature. CDI (725 mg 4.5 mmol, 1.1 eq) was added at room temperature in one portion. Full conversion of 9-3 was obtained after 2 h (IPC: TLC BuOH, AcOH, water 5:1:1). The volatiles were evaporated and the crude product was purified by column chromatography. (S)-4-(difluoromethyl)oxazolidin-2-one 10-2 was obtained as pale yellow oil (308 mg, 55% o. th., single enantiomer). 1 H NMR (300 MHz, DMSO-d 6 ) δ = 8.26 (s, 1H), 6.09 (td, 1H, J = 55.3 Hz, J = 3.3 Hz, H4), 4.41 (tt, J = 9.3 Hz, J = 1.1 Hz, 1H), 4.25 (dd, J = 9.3 Hz, J = 4.2 Hz, H3), 4.22 – 4.08 (m, 1H, H2). Scheme 3 Scheme 3 Step (i): Hemiacetal 2 (5.0 g, 40 mmol, 1.0 eq) and (S)-tert-butylsulfinamide (4.8 g, 40 mmol, 1.0 eq) was dissolved in toluene (25 ml, 5 V). The mixture was refluxed with a Dean-Stark trap for 5 h. The solvent was distilled off. The crude product was purified by distillation under reduced pressure at 100°C. (S,E)-N-(2,2-difluoroethylidene)-2-methylpropane-2-sulfinami de was obtained as colorless liquid (1.1 g, 18% yield o. th). 1 H NMR (300 MHz, Chloroform-d) δ 8.07 (dt, J = 4.7, 3.1 Hz, 1H), 6.28 (td, J = 54.6, 4.7 Hz, 1H), 1.27 (s, 9H). Scheme 3 Step (ii): (S,E)-N-(2,2-difluoroethylidene)-2-methylpropane-2-sulfinami de (13 g, 71 mmol, 1.0 eq) was dissolved in DCM (130 ml, 10 V). Y(OTf)3 (3.8 g, 7.1 mmol, 10 mol%) was added and the suspension was stirred for 15 min. TMSCN (18 ml, 142 mmol, 2.0 eq) was added over 30 min at room temperature. The Reaction mixture was stirred for 4 h until full conversion of (S,E)-N-(2,2- difluoroethylidene)-2-methylpropane-2-sulfinamide was reached (TLC: EtOAc). The reaction was quenched by the addition of water (50 ml). The organic layer was washed 2 x with water 50 ml and the solvent was distilled off. The diastereomeric ratio of the crude product was 5:1 (NMR). The crude product was purified by column chromatography (EtOAc cyclohexane 1:3 to 1:1). The diastereomerically pure (S)-N-((R)-1-cyano-2,2-difluoroethyl)-2-methylpropane-2-sulf inamide was obtained as light brown solid (11 g, 73% o. th). 1 H NMR (300 MHz, Chloroform-d) δ 5.95 (ddd, J = 55.0, 54.3, 3.2 Hz, 1H), 4.61 (dddd, J = 14.2, 9.2, 8.4, 3.2 Hz, 1H), 1.29 (s, 9H). Scheme 3 Step (iii): (S)-N-((R)-1-cyano-2,2-difluoroethyl)-2-methylpropane-2-sulf inamide (6.0 g, 29 mmol, 1.0 eq) was dissolved in 33% HCl (30 ml, 5 V). The mixture was heated gently to 80°C and stirred for 4 h until full conversion of the (S)-N-((R)-1-cyano-2,2-difluoroethyl)-2- methylpropane-2-sulfinamide(TLC: EtOAc). The volatiles were removed under reduced pressure. Methanol (10 V) was added and the suspension was stirred for 30 min at room temperature. The solid (NH4Cl) was filtered off and the filter cake was washed with methanol (1.0 V). Methanol was removed and the residue was suspended in TBME (10 V) and stirred for 30 min at room temperature. The suspension was filtered off and the wet product was dried under reduced pressure. Amino acid hydrochloride 9-2 was obtained as light brown solid (4.3 g, 93% o. th.). 1 H NMR (300 MHz, Deuterium Oxide) δ 6.46 (td, J = 52.8, 1.9 Hz, 1H), 4.70 (s, 4H), 4.40 (dt, J = 25.8, 1.9 Hz, 1H). Scheme 3 Step (iv): 9-2 9-3 Amino acid hydrochloride 9-2 (1.0 g, 6.6 mmol, 1.0 eq) was suspended in THF (5 ml, 5 V). BH31.0 M in THF (20 ml, 3.0 eq) was added at 0°C over 30 min. Vigorous gas evolution was observed. The suspension was heated to 45°C for 2 h. Full conversion of the starting material was obtained after 2 h (IPC: TLC BuOH, AcOH, water 5:1:1). The mixture was quenched with methanol (5 ml, 5 V) and acetic acid (5 ml, 5 V) at room temperature. The volatiles were evaporated and the residue was taken up in HCl 33% (1.5 ml, 1.5 V). The volatiles were evaporated and the solid was dried under reduced pressure. The crude amino alcohol hydrochloride 9-3 was directly used for the next step. 1 H NMR (300 MHz, DMSO-d 6 ) δ 8.78 (s, 3H), 6.31 (td, 1H, J = 54.3 Hz, J = 3.9 Hz, H3), 5.63 (s, 1H, OH), 3.88 – 3.66 (m, 2H, H1), 3.65- 3.50 (m, 1H, H2). Scheme 3 Step (v): The crude mixture from amino alcohol hydrochloride 9-3 was mixed with triethylamine (0.92 ml, 18 mmol, 3.0 eq) and IPAc (5 ml, 5 V) at room temperature. CDI (1.24 g, 2.0 eq) was added at room temperature in one portion. Full conversion of amino alcohol 9-3 was obtained after 2 h (IPC: TLC 1-BuOH, AcOH, water 5:1:1). The volatiles were evaporated and the crude product was purified by column chromatography. (S)-4-(difluoromethyl)oxazolidin-2-one 10-2 was obtained as pale yellow oil (450 mg, 50% o. th. over two steps). The ratio of the enantiomers was 89:11. 1 H NMR (300 MHz, Chloroform-d) δ 6.33 (s, 1H), 5.71 (td, J = 55.3, 4.5 Hz, 1H), 4.46 (td, J = 9.2, 1.3 Hz, 1H), 4.35 (dd, J = 9.6, 4.5 Hz, 1H), 4.04 (ddq, J = 13.9, 9.3, 4.5 Hz, 1H). Scheme 4 Scheme 4 Step (a): Benzyloxy acetaldehyde 11 (2.50 g, 16.7 mmol, 1.0 eq) and (R)-tert-butylsulfinamide 3 (2.15 g, 18.3mmol, 1.1 eq) were dissolved in DCM (25 ml, 10 V). Copper sulfate (6.44 g, 41.8 mmol, 2.5 eq) was added and the suspension was stirred for 16 h at 25°C until full conversion of 11 was reached (TLC: EtOAc heptane 1:1). Celite (10 g) was added and the suspension was filtered over silica (10 g). The filter cake was rinsed with DCM (50 ml, 20 V) and the solvents were evaporated. Sulfinimide 12 was obtained as yellow oil (4.05 g, quantitative yield). 1 H NMR (300 MHz, Chloroform-d) δ 8.06 (t, J = 3.3 Hz, 1H), 7.34 – 7.20 (m, 5H), 4.56 (s, 2H), 4.33 (dd, J = 3.2, 1.0 Hz, 2H), 1.14 (s, 9H). Scheme 4 Step (b): Sulfinimide 12 (600 mg, 2.4 mmol, 1.0 eq) and difluoromethylphenylsulfone 13 (500 mg, 2.6 mmol, 1.1 eq) were dissolved in THF (12 ml, 20 V). The solution was cooled down to -78°C. NaHMDS 40% in THF (1.3 g, 2.8 mmol, 1.2 eq) was added over 5 min at -78°C. The purple solution was stirred for 15 min. Full conversion was reached (TLC, EtOAc/heptane 1:1). The reaction mixture was quenched with saturated NaHCO3 solution (20 ml). The aqueous layer was extracted with EtOAc (50 ml). The organic layers were dried over MgSO 4 and the solvent was evaporated. Sulfone 14 was obtained as a light brown oil (1.05 g, quantitative yield). 1 H NMR (300 MHz, Chloroform-d) δ 7.81 (d, J = 7.4 Hz, 2H), 7.65 – 7.55 (m, 1H), 7.46 (t, J = 7.7 Hz, 2H), 7.25 – 7.11 (m, 5H), 4.49 (d, J = 11.8 Hz, 1H), 4.41 (d, J = 11.8 Hz, 1H), 4.25 (ddddd, J = 15.2, 10.8, 9.2, 4.4, 3.3 Hz, 1H), 4.06 (d, J = 9.2 Hz, 1H), 3.90 (ddd, J = 10.5, 3.3, 1.4 Hz, 1H), 3.81 (dd, J = 10.5, 4.4 Hz, 1H), 1.12 (s, 9H). Scheme 4 Step (c): Sulfone 14 (7.03 g, 15.7 mmol, 1.0 eq) was dissolved in DMF (105 ml, 15 V) and acetate buffer (5.0 g acetic acid, 6.4 g NaOAc, 13 g water). Magnesium tunings (5.67 g, 23.5 mmol, 15 eq) were added in one portion and the suspension was stirred for 3 h at 30°C until full conversion of sulfone 14 was reached (TLC: EtOAc). Remaining magnesium tunings were filtered off and the reaction mixture was quenched on MTBE/water (2.0 V). The aqueous layer was extracted three times with MTBE (150 ml). The organic layers were combined and washed with water (50 ml). The volatiles were distilled off and the crude product was purified by column chromatography (EtOAc heptane 1:1 to 2:1). The sulfinamide 8-1 was obtained as single diasteromer (2.3 g, 48% o. t.). 1 H NMR (300 MHz, Chloroform-d) δ 7.40 – 7.14 (m, 5H), 5.75 (ddd, J = 56.4, 55.5, 4.7 Hz, 1H), 4.51 (d, J = 11.7 Hz, 1H), 4.43 (d, J = 11.8 Hz, 1H), 3.76 (ddd, J = 9.7, 3.6, 2.2 Hz, 2H), 3.69 – 3.61 (m, 1H), 3.55 (dddd, J = 11.9, 8.3, 4.9, 2.6 Hz, 1H), 1.16 (s, 9H). Scheme 4 Step (d): Sulfinamide 8-1 (2.00 g, 6.6 mmol, 1.0 eq) was dissolved in methanol (10 ml, 5.0 V). Hydrochloric acid 37% (0.65 ml, 7.9 mmol, 1.2 eq) was added at room temperature and the reaction mixture was stirred for 3 h until full conversion was reached (TLC: EtOAc heptane 1:1). The volatiles were distilled off. The residue was suspended in MTBE (20 ml, 10 V). The solid was filtered off and dried under vacuum. Benzyl ether 9-5 was obtained as white solid (1.23 g, 79% o. t.). 1 H NMR (300 MHz, DMSO-d 6 ) δ 8.93 (s, 3H), 7.45 – 7.27 (m, 5H), 6.37 (td, J = 54.1, 3.7 Hz, 1H), 4.57 (d, J = 2.7 Hz, 2H), 3.96 – 3.82 (m, 1H), 3.82 – 3.65 (m, 2H). Scheme 4 Step (e): Benzyl ether 9-5 (1.1 g, 4.6 mmol, 1.0 eq) was dissolved in methanol (10 ml, 5.0 V) and Pd/C 5.0% (200 mg) was added. The tube was purged 3 x with hydrogen. The reaction mixture was stirred for 5 h under 20 bar hydrogen at room temperature until full conversion of benzyl ether 9-5 was obtained (TLC: DCM MeOH 20:1). The catalyst was filtered off and the solvent was distilled off. The residue was suspended in MTBE (20 ml, V). The solid was filtered off and dried under vacuum. The amino alcohol hydrochloride 9-2 was obtained as white solid (0.53 g, 78% yield o. th.). 1 H NMR (300 MHz, DMSO-d 6 ) δ 8.78 (s, 3H), 6.31 (td, 1H, J = 54.3 Hz, J = 3.9 Hz, H3), 5.63 (s, 1H, OH), 3.88 – 3.66 (m, 2H, H1), 3.65-3.50 (m, 1H, H2). Scheme 4 Step (f): Amino alcohol hydrochloride 9-2 (0.44 g, 3.0 mmol, 1.0 eq) was suspended in THF (5 ml, 11V). DIPEA (1.15 ml, 9.0 mmol, 2.0 eq) was added and the suspension was stirred for 30 min at room temperature. CDI (0.72 g, 4.4 mmol, 1.5 eq) was added and the reaction mixture was stirred for 16 h at room temperature until full conversion of 8 was reached. The reaction mixture was absorbed on silica and purified by column chromatography. The enantiomer of (S)-4- (difluoromethyl)oxazolidin-2-one 10-2 was obtained as colorless oil (180 mg, 44% o. th., single enantiomer). 1 H NMR (300 MHz, Chloroform-d) δ 6.33 (s, 1H), 5.71 (td, J = 55.3, 4.5 Hz, 1H), 4.46 (td, J = 9.2, 1.3 Hz, 1H), 4.35 (dd, J = 9.6, 4.5 Hz, 1H), 4.04 (ddq, J = 13.9, 9.3, 4.5 Hz, 1H). Scheme 5 Scheme 5 Step a: Into a suspension of 2-(5-bromo-2-cyanophenoxy)ethan-1-aminium chloride 11′ (20.4 kg, 97.8 wt %, 71.9 mol, 100 mol %) in MeOH (64.0 kg), solid magnesium ethoxide, Mg(OEt) 2 (17.9 kg, 219 mol %) was charged. The mixture was agitated at 25 °C for 30 min and followed by the addition of 2-methyltetrahydrofuran, 2-MeTHF (140 kg), the reaction mixture was heated to reflux and stirred for 40 h. After the reaction was completed, the batch was concentrated to approximately 50 L under reduced pressure below 40 °C. Followed by the addition of 2-MeTHF (172 kg), a solution of hydrogen chloride in n-propanol (83.0 kg, 5.00 M) was added below 15 °C. The suspension was stirred at 15 °C for 4 h and filtered. The resulting solid was washed with 2- MeTHF (10 kg) and dried under reduced pressure at 50 °C to afford 8-bromo-2,3- dihydrobenzo[f][1,4]oxazepin-5-amine hydrochloride 12′ (17.6 kg, 88% yield) as a hygroscopic solid that was used as is for the next step. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.32 (s, 3H), 7.74 (d, J = 8.3 Hz, 1H), 7.61 (d, J = 1.5 Hz, 1H), 7.38 (dd, J = 8.3, 1.5 Hz, 1H), 4.44 (t, J = 5.2 Hz, 2H), 3.24 (t, J = 5.2 Hz, 2H). Scheme 5 Step b: Into a mixture of 8-bromo-2,3-dihydrobenzo[f][1,4]oxazepin-5-amine hydrochloride 12′ (17.6 kg, 63.4 mol, 100 mol %) and 2-MeTHF (122 kg) were charged a 40% chloroacetaldehyde aqueous solution (16.4 kg, 132 mol %) and water (10 kg). The mixture was heated to 40 ºC and aqueous potassium bicarbonate solution was charged. The reaction mixture was stirred at 45 ºC for 21 h. After the reaction was complete, the reaction mixture was cooled to 20 ºC, stirred for 30 min, and filtered. The resulting cake was rinsed with 2-MeTHF (33.0 kg) and the combined filtrates were allowed to settle. The resulting organic layer was washed with aqueous sodium bisulfite solution (30 kg), concentrated to approximately 26 L under reduced pressure below 45 ºC. After the addition of DMF (25 kg), the mixture was concentrated to approximately 26 L under reduced pressure below 45 ºC. Water (154 kg) was charged at 40 ºC followed by the seed of 9- bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine 13′ (1.20 kg). The mixture was stirred at 40 ºC for another 1.5 h and cooled to 20 ºC. After stirring for 10 h at 20 ºC, the suspension was filtered. The resulting solid was washed with water twice (25 kg x 2) and dried under reduced pressure at 45 ºC to afford 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine 13′ (16.3 kg, 97.5 wt %, 95% yield). 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.33 (d, J = 8.6 Hz, 1H), 7.35 (s, 1H), 7.31–7.22 (m, 2H), 7.06 (s, 1H), 4.45 (q, J = 5.3 Hz, 4 H); HRMS calcd. For C 11 H 10 BrN 2 O [M+H] + : 264.9971, found 264.9976. Scheme 5 Step c: Into a solution of 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine 13′ (16.3 kg, 97.5 wt %, 59.9 mol, 100 mol %) in DMF (78.0 kg) was added N-iodosuccinimide (NIS) (29.0 kg, 215 mol %) at 40 ºC. The reaction mixture was slowly heated to 70 ºC and stirred for 6 h. After the reaction was complete, 10% aqueous sodium sulfite solution (78.0 kg) was charged at 45 ºC followed by water (154 kg). The resulting suspension was stirred at 45 ºC for 1 h and cooled to 20 ºC. After stirring at 20 ºC for 8 h, the suspension was filtered. The resulting solid was washed with water (160 kg) and dried under reduced pressure at 45 ºC to afford 9-bromo-2,3-diiodo-5,6- dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine 14′ (29.7 kg, 100 wt %, 96% yield) as an off-white solid. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.21 (d, J = 8.6 Hz, 1H), 7.32–7.24 (m, 2H), 4.51–4.45 (m, 2H), 4.39–4.34 (m, 2H); HRMS calcd. For C 11 H 8 BrI 2 N 2 O [M+H] + : 516.7904, found 516.7911. Scheme 5 Step d: Into a solution of 9-bromo-2,3-diiodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxa zepine 14′ (39.4 kg, 76.2 mol, 100 mol %) in tetrahydrofuran, THF (180 kg) was added a solution of 2.0 M ethylmagnesium bromide in 2-methyltetrahydrofuran (44.0 kg, 120 mol %) at 10 ºC. The reaction mixture was stirred at 10 ºC for 2 h. After the reaction was complete, 5% acetic acid (133 kg) was charged while maintaining the batch temperature below 30 ºC. Ethyl acetate (168 kg) was charged and the resulting mixture was stirred at 20 ºC for 1 h. The layers were separated and the aqueous layer was extracted with ethyl acetate (77.8 kg). The combined organic layers were washed with water (76.0 kg) and filtered through a pad of silica gel (19.8 kg). The silica gel pad was rinsed with ethyl acetate (69.6 kg). The combined filtrates were concentrated to approximately 100 L under reduced pressure below 50 ºC and THF (146 kg) was added. The resulting mixture was heated to 60 ºC until a clear solution was obtained before it was concentrated to approximately 100 L under reduced pressure below 50 ºC and then cooled to 30 ºC. n-Heptane was charged (86.8 kg) and the resulting mixture was stirred at 30 ºC for 2 h. The batch was solvent-switched to n-heptane by three cycles of batch concentration under reduced pressure below 35 ºC to approximately 180 L and n-heptane addition (47.6 kg ^ ^ 3). The resulting suspension was cooled to 20 ºC, stirred for 12 h, and filtered. The resulting solid was washed with n-heptane (64.0 kg) and dried under reduced pressure at 45 ºC to afford 9-bromo-2-iodo-5,6- dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine 15 (25.3 kg, 98.7 wt %, 84% yield) as a light tan solid.. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.23 (d, J = 8.6 Hz, 1H), 7.55 (s, 1H), 7.32–7.24 (m, 2H), 4.44 (q, J = 5.4 Hz, 4H); HRMS calcd. For C 11 H 9 BrIN 2 O [M+H] + : 390.8937, found 390.8949. Scheme 5 Step e: 9-Bromo-2-iodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepi ne 15 (6.90 kg, 98.7 wt %, 17.4 mol, 100 mol %) was charged to a reactor, followed by (S)-4-(difluoromethyl)oxazolidin- 2-one (10-2) (2.68 kg, 112 mol %), copper (II) acetate (0.653 kg, 20.6 mol %), and Cs 2 CO 3 (11.7 kg, 206 mol %). The reactor was evacuated and backfilled with nitrogen three times.2- Methyltetrahydrofuran (36.0 kg) and trans-N,N-dimethylcyclohexane-1,2-diamine (0.764 kg, 30 mol %) was then charged into the reactor. The reactor was evacuated and backfilled with nitrogen three times. The reaction mixture was heated to 78 ºC and stirred for 22 h. After the reaction was complete, a 20 wt % NaHSO 4 aqueous solution (42.0 kg) was slowly added while maintaining the internal temperature between 60–70 ºC. The layers were separated at 65 ºC and the aqueous layer was removed. The batch was solvent-switched to acetonitrile via a constant volume distillation under reduced pressure at 60–70 ºC by adding acetonitrile (62.3 kg). Water (14.1 kg) was added into the reactor while maintaining the batch temperature between 60–70 ºC. The suspension was cooled to 20 ºC at a rate of 0.5 ºC/min, stirred for 18 h, and filtered. The resulting solid was washed with a mixture of acetonitrile and water (50 kg, 44:56, w/w) and dried under reduced pressure at 90 ºC to afford (S)-3-(9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepi n-2-yl)- 4-(difluoromethyl)oxazolidin-2-one 16 as a tan solid (5.85 kg, 91.9 wt %, 77% yield). 1 H NMR (500 MHz, CDCl 3 ) δ 8.22 (d, J = 8.8 Hz, 1H), 7.31 (s, 1H), 7.28–7.19 (m, 2H), 6.71–6.62 (m, 1H), 4.90 (ddd, J = 24.0, 9.3, 3.8 Hz, 1H), 4.75 (dd, J = 9.4, 3.9 Hz, 1H), 4.56 (t, J = 9.3 Hz, 1H), 4.51–4.44 (m, 2H), 4.41–4.35 (m, 2H); HRMS calcd. For C 15 H 13 BrF 2 N 3 O 3 [M+H] + : 400.0103, found 400.0134. Scheme 5 Step f: (S)-3-(9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepi n-2-yl)-4-(difluoromethyl) oxazolidin-2-one 16 (3.96 kg, 91.9 wt %, 9.19 mol, 100 mol %) was charged to a reactor, followed by (S)-2-aminopropanoic acid (L-alanine) (2.49 kg, 307 mol %), K 3 PO 4 (5.84 kg, 303 mol %), and DMSO (19.9 kg). The mixture was sparged with nitrogen for 1 h and heated to 95 ºC. A slurry of copper (I) oxide (67.1 g, 5.16 mol %) in DMSO (2.21 kg) that was pre-sparged with nitrogen for 30 min was then transferred to the reactor. The reaction mixture was stirred at 95 ºC for 4 h. After the reaction was complete, the reaction mixture was cooled to 20 ºC. DCM (37.3 kg) was added to the reactor, followed by water (24.2 kg). The layers were separated and the organic layer was removed. The aqueous layer was washed with dichloromethane, DCM (26.6 kg) one more time. THF (35.2 kg) and an aqueous sodium bisulfate solution (19 wt %, 20.7 kg) were charged to the reactor sequentially. The layers were separated and the aqueous layer was removed. The organic layer was washed with 15 wt % brine (2 ^ 12 kg). SiliaMetS® DMT (Silicycle Inc., 1.60 kg) was charged and the batch was stirred at 25 ºC for 15 h and filtered to scavenge residual metal. SiliaMetS® DMT is the silica-bound equivalent of 2,4,6- trimercaptotriazine (trithiocyanuric acid, TMT), and a versatile metal scavenger for a variety of metals including ruthenium catalysts and hindered Pd complexes. Tetrahydrofuran, THF (24.8 kg) was used to rinse the filter. The combined filtrates were heated to 50 ºC. A 7 N solution of ammonia in methanol (1.02 kg, 100 mol %) was added followed by a slurry of seeds (ammonium (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6- dihydrobenzo[f]imidazo[1,2- d][1,4]oxazepin-9-yl)amino)propionate 17, 19.5 g) in THF (0.395 kg). The resulting suspension was stirred at 50 ºC for 2 h and a constant volume distillation was conducted at 40–60 ºC under reduced pressure to remove residual water by adding anhydrous THF (60.1 kg). A 7 N solution of ammonia in methanol (1.02 kg, 100 mol %) was added. The suspension was stirred at 50 ºC for 15 h and filtered. The resulting solid was washed with THF (21.8 kg) and dried under reduced pressure at 25 ºC to afford ammonium (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)- 5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)pr opionate 17 as a beige solid (3.19 kg, 98.0 wt %, 81% yield). 1 H NMR (DMSO-d 6 ) δ 7.97 (d, J = 8.8Hz, 1H), 7.16 (s, 1H), 6.74 – 6.69 (m, 1H), 6.38 (dd, J = 9.0, 2.2 Hz, 1H), 6.07 (d, J = 2.2Hz, 1H), 5.02 – 4.91 (m, 1H), 4.64 – 4.52 (m, 2H), 4.40 – 4.30 (m, 4H), 3.63 (q, J = 6.1, 5.5Hz, 1H), 1.27 (d, J = 6.7Hz, 3H). HRMS calcd. For C18H19F2N4O5 [M+H] + : 409.1318, found 409.1318. Scheme 5 Step g: Ammonium (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6- dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propio nate 17 (5.60 kg, 13.2 mol, 100 mol %) was charged to a reactor, followed by N-hydroxysuccinimide, HOSu (1.52 kg, 102 mol %) and THF (49.6 kg). The batch was sparged with nitrogen for 40 min and cooled to 10 ºC. A 2 N solution of ammonia in 2-propanol (5.05 kg, 101 mol %) and N-(3-dimethylaminopropyl)-N'- ethylcarbodiimide hydrochloride, EDC (5.20 kg, 210 mol %) were charged sequentially to the reactor. The reaction mixture was stirred at 10 ºC for 20 h. After the reaction was complete, the mixture was warmed up to 20 ºC and 15 wt % brine (33.7 kg) was added. The layers were separated at 35 ºC and the aqueous layer was removed. The organic layer was washed sequentially with 15 wt % brine (2 ^ 16.9 kg) and a mixture of 15 wt % brine (8.97 kg) and 28.0–30.0 wt % ammonium hydroxide (7.55 kg) and then filtered through a polishing filter unit. The filter unit was rinsed with THF (5.05 kg). The combined filtrates were distilled under reduced pressure at 50 ºC to approximately half of its original volume. Ethanol (8.90 kg) was charged at 50 ºC, followed by a slurry of seeds ((S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6 - dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propan amide 18, 27.1 g) in ethanol (0.340 kg). The resulting suspension was stirred at 50 ºC for 30 min and solvent-switched to ethanol via a constant volume distillation under reduced pressure at 40–60 ºC by adding ethanol (39.9 kg). Water (0.379 kg) was added at 50 ºC. The suspension was cooled to 20 ºC, stirred for 23 h, and filtered. The resulting solid was washed with a 90:10 (w/w) mixture of ethanol and water (27.9 kg) and dried under reduced pressure at 80 ºC to afford (S)-2-((2-((S)-4-(difluoromethyl)-2- oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]ox azepin-9-yl)amino)propanamide 18 as a light pink solid (4.37 kg, 99.7 wt %, 83% yield). 1 H NMR (600 MHz, CD 3 CN) δ 8.08 (d, J = 8.8 Hz, 1H), 7.11 (s, 1H), 6.86–6.50 (m, 1H), 6.41 (dd, J = 8.8, 2.3 Hz, 1H), 6.12 (d, J = 2.4 Hz, 1H), 4.87 (dd, J = 23.8, 8.8 Hz, 1H), 4.67–4.50 (m, 2H), 4.43–4.33 (m, 2H), 4.33–4.26 (m, 2H), 3.82 (q, J = 7.0 Hz, 1H), 1.41 (d, J = 7.0 Hz, 3H) (Note: N-H protons were omitted for clarity); 13 C NMR (151 MHz, CD 3 CN) δ 178.2, 157.0, 155.1, 149.1, 141.6, 135.4, 130.8, 113.3, 108.9, 108.1, 107.7, 102.1, 68.5, 61.7, 56.1, 53.1, 49.6, 18.2; HRMS calcd. For C 18 H 20 F 2 N 5 O 4 [M+H] + : 408.1478, found 408.1473. Scheme 5 (Alternatives) Scheme 5 Step b (Alternative) Into a mixture of 8-bromo-2,3-dihydrobenzo[f][1,4]oxazepin-5-amine hydrochloride (40.00 g, 144 mmol) and 2-MeTHF (444 g, 520 mL) were charged a 46% chloroacetaldehyde aqueous solution (39.27 g, 231 mmol, 1.6 equiv.) and water (20 mL). The mixture was heated to 65 ºC and solution of potassium bicarbonate (45.45 g, 454 mmol, 3.15 equiv.) in water (161 mL) was added over 2 h. The reaction mixture was stirred at 65 ºC for 0.5 h. The aqueous layer was separated and the resulting organic layer was concentrated to approximately 200 mL under reduced pressure. Ethanol (200 mL, 156 g) was added and the resulting mixture was concentrated to approximately 200 mL under reduced pressure. Ethanol (200 mL, 156 g) was added and the resulting mixture was concentrated to approximately 200 mL under reduced pressure. Ethanol (200 mL, 156 g) was added and the resulting mixture was concentrated to approximately 200 mL under reduced pressure and warmed to 50 °C. To the resulting solution water (200 g, 200 mL) was added over 1.5 h followed by the seed of 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2- d][1,4]oxazepine (200 mg). The mixture was stirred at 50 ºC for another 1.0 h and cooled to 0 ºC over 6 h. After stirring for min.1 h at 0 ºC, the suspension was filtered. The resulting solid was washed with water three times (50 mL x 3) and dried under reduced pressure at 50 ºC to afford 9- bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine (33.9 g, 100.0 wt %, 89% yield). Scheme 5 Step c (Alternative) Into a solution of 9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine (20 g, 75.4 mmol) in MeCN (139 g, 177 mL) was added iodine (19.15 g, 75.4 mmol, 1.0 equiv.), sodium periodate (9.68 g, 45.3 mmol, 0.6 equiv), and MeCN (10 g, 17.2 mL) at 25 °C. Aqueous sulfuric acid 10% (37.00 g, 75.4 mmol, 1.0 equiv) was added over 0.5 h. The reaction mixture was heated to 60 ºC over 0.5 h and stirred for 13 h before it was cooled to 30 °C over 0.5 h. A solution of sodium sulfite (18.54 g, 147 mmol, 1.95 equiv.) in water (210 g, 210 mL) was added over 2 h. The resulting suspension was stirred at 30 ºC for min.1 h and filtered. The resulting solid was washed with water twice (2x 40g) and dried under reduced pressure at 50 ºC to afford 9-bromo- 2,3-diiodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine (36.8 g, 100.0 wt %, 94.4% yield). Scheme 5 Step d (Alternative) Into a mixture of 9-bromo-2,3-diiodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxa zepine (1.30 kg, 2.51 mol, 1.0 equiv) and toluene (11.3 kg) was added a solution of 24% ethylmagnesium bromide in 2-methyltetrahydrofuran (2.00 kg, 3.60 mmol, 1.4 equiv.) at -10 ºC over 1.5 h. The reaction mixture was stirred at -10ºC for 1 h before it was transferred onto a solution of 80% acetic acid (1.04 kg, 13.9 mmol, 5.5 equiv.) in water (7.2 kg) at 15-20 °C over 1 h. The mixture was heated to 60 °C before the aqueous phase was separated and the organic phase was washed with water twice (2 x 7.2 kg). The resulting organic layer was concentrated to approximately 6.5 L under reduced pressure. After the solution was heated to 85 °C, heptane (14.3 kg) was added over 1.5 h. The mixture was cooled to 10 °C over 8 h. After stirring for min.1 h at 0 ºC, the suspension was filtered. The resulting solid was washed with heptane twice (2 x 2.7 kg) and dried under reduced pressure at 50 ºC to afford 9-bromo-2-iodo-5,6-dihydrobenzo[f]imidazo[1,2- d][1,4]oxazepine 15 (0.94 kg, 98.9 wt %, 95.8% yield). Scheme 5 Step e (Alternative) A suspension of 9-bromo-2-iodo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepi ne (15.00 g, 38.34 mmol, 1.0 equiv.), (S)-4-(difluoromethyl)oxazolidin-2-one (5.78 g, 42.2 mmol, 1.1 equiv), trans-N,N-dimethylcyclohexane-1,2-diamine (0.818 g, 5.75 mmol, 0.15 equiv), and Cs2CO3 (31.2 g, 95.9 mmol, 2.5 equiv) in 2-Methyltetrahydrofuran (120 mL, 102 g) was thoroughly purged with argon. Copper(I) iodide (0.365 g, 1.92 mmol, 0.05 equiv.) was then added and the reaction mixture was heated to 70 ºC and stirred for 46 h. The mixture was cooled to 60 °C, and diluted with THF (120 mL) before 5% aqueous solution of NH4OH (44 mL) was added. The phases were separated and the organic phase was washed with 5% aqueous solution of NH 4 OH twice (2 x 44 mL). The resulting organic layer was concentrated to approximately 90 mL under reduced pressure. The distillation was continued with continuous addition of acetonitrile (200 mL) at constant volume. The resulting suspension was heated to 60 °C and water (35 g) was added over 20 min. The mixture was cooled to 20 °C over 1.5 h. After stirring for min.1 h at 20 ºC, the suspension was filtered. The resulting solid was washed with a mixture of acetonitrile (39 g) and water (18 g) in three portions and dried under reduced pressure at 50 ºC to afford (S)-3-(9- bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-2-yl)-4 -(difluoromethyl)oxazolidin-2-one (13.79 g, 100.5 wt %, 90% yield). Scheme 5 Step f (Alternative) (S)-3-(9-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepi n-2-yl)-4-(difluoromethyl) oxazolidin-2-one (33 g, 81.1 mmol, 1.0 equiv.) was charged to a reactor, followed by (S)-2- aminopropanoic acid (L-alanine) (21.69 g, 243.4 mmol, 3.0 equiv.), Cu(I) oxide (0.290 g, 2.0 mmol, 0.025 equiv), and K 3 PO 4 (51.67 g, 243.4 mmol, 3.0 equiv). The reactor was evacuated and backfilled with nitrogen three times. DMSO (167 mL, 183 g) was added and the reactor was evacuated and backfilled with nitrogen three times. The mixture was heated to 95 ºC. A slurry of copper (I) oxide (67.1 g, 5.16 mol %) in DMSO (2.21 kg) that was pre-sparged with nitrogen for 30 min was then transferred to the reactor. The reaction mixture was stirred at 95 ºC for 6 h. After the reaction was complete, the reaction mixture was cooled to 20 ºC. A solution of Ammonium pyrrolidinedithiocarbamate (12 mmol, 0.15 eq.) dissolved in (212 mL) Water and (232 mL) 2- MeTHF was added and the mixture was stirred for 2 h. The lowest of three liquid phases was separated and the mixture was filtered. The upper organic pahse was discarded and the lower aqueous phase was washed with 2-MeTHF (132 mL). The the aquous phase was added 2- MeTHF(660 mL) and a 20% aquous solution of sodium hydrogen sulfate (171.5 g). The mixture was stirred for 20 min and filtered and the filter was rinsed with 2-MeTHF (99 mL). The aqueous phase was separated. To The resulting organic phase was added acetonitrile (99 mL), a solution of ammonia in methanol (7N, 3.4 mL, 24 mmol, 0.3 equiv) and the seed of ammonium (S)-2-((2- ((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydroben zo[f]imidazo[1,2-d][1,4]oxazepin- 9-yl)amino)propionate (10 mg). The mixture was stirred for 2 h before additional solution of ammonia in methanol (7N, 14.0 mL, 98 mmol, 1.2 equiv) was added over 2 h. The resulting suspension was stirred for min.12 h and filtered. The resulting solid was washed with 2-MeTHF twice (2 x 200 mL) and dried under reduced pressure at 50 ºC to afford ammonium (S)-2-((2-((S)- 4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f] imidazo[1,2-d][1,4]oxazepin-9- yl)amino)propionate (29.9 g, 87% yield). Scheme 5 Step g (Alternative) To a suspension of ammonium (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)- 5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)pr opionate (25.0 g, 58.8 mmol, 1.0 equiv.)) in THF (250 mL) was added N-hydroxysuccinimide (1.35 g, 11.8 mmol, 0.2 equiv), ammonium bicarbonate (2.32 g, 29.4 mmol, 0.5 equiv.), N,N-Diisopropylcarbodiimid (8.90 g, 10.99 mL, 70.5 mmol, 1.2 equiv.), and N-methylmorpholine (4.16 g, 4.57 mL, 41.1 mmol, 0.7 equiv.). The mixture was stirred for 16 h at 25 °C. A 10% aqueous solution of sodium chloride (150 mL) was added and the mixture was heated to 40 °C. The aqueous phase was separated and the organic layer was washed with a mixture of 10% aqueous solution of sodium chloride (80 mL) and 5% aqueous solution of sodium hydrogen carbonate (40 mL) twice. The organic solution was washed with 10% aqueous solution of sodium chloride (80 mL) and heated to 50 °C, and concentrated to approximately 125 mL under reduced pressure.1-Propanol (125 mL) was added and the resulting mixture was concentrated to approximately 125 mL under reduced pressure.1- Propanol (125 mL) was added and the resulting mixture was concentrated to approximately 125 mL under reduced pressure and warmed to 50 °C. The suspension was cooled to 20 ºC over 2 h, stirred for 4 h, and filtered. The resulting solid was washed with a 1-propanol (75 mL), water (75 mL), and 1-propanol (75 mL) and dried under reduced pressure at 60 ºC to afford (S)-2-((2-((S)-4- (difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]im idazo[1,2-d][1,4]oxazepin-9- yl)amino)propanamide (20.18 g, 97.8 wt%, 82% yield). Scheme 5 Step d - Continuous flow process A continuous flow process consisted of simultaneous addition of 9-bromo-2,3-diiodo-5,6- dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine (compound 14′) (1.00 equiv, 0.223 M in THF) and EtMgBr (1.45 equiv, 40.0 wt% in MeTHF) in pipe reactor 1 (JT 10 ºC, T res ca.30 s), followed by aqueous acetic acid (2.25 equiv, 14.5 wt% in water) in pipe reactor 2 (JT 10 ºC, T res ca.30 s). The biphasic reaction mixture exiting pipe reactor 2 was directed through a heat exchanger to the receiving tank. The quenched reaction mixture was collected over a specified period of time and yield was calculated based on the flow rate of compound 14′ (mmol/min) and run time. The biphasic reaction mixture from the continuous process was diluted with toluene, extracted with an aqueous solution of NaHCO3 and water. The organic phase was concentrated, anti-solvent heptane was added and the product 9-bromo-2-iodo-5,6-dihydrobenzo[f]imidazo[1,2- d][1,4]oxazepine (compound 15) was filtered and dried under vacuum to yield compound 15 as a pink powder in 92 – 96% yield. Analysis of 14 C labeled inavolisib (2S)-2-[[2-[(4S)-4-(difluoromethyl)-2-keto-oxazolidin-3-yl]- 5,6-dihydro[2- 14 C]imidazolo[1,2-d][1,4]benzoxazepin-9-yl]amino]propion amide (14.4 mCi, 107.7 mg of light brown, beige solid) was made according to Scheme 6 and analyzed by HPLC. HPLC Method: Column: XBridge C18; 3.5 μm (3.0 x 100 mm). Mobile Phase A: water/acetonitrile 95:5 + 0.1% Phosphoric acid. Mobile Phase B: acetonitrile. Conditions: 0% B, 0- 2 min; 0-15% B, 2-18 min; 15-90% B, 18-26 min; 90% B 26-28 min. Flow rate: 0.8 mL/min. Temperature: 35 °C. The UV purity (λ: 330 nm) was 98.8% (retention time: 13.4 min) and radiochemical purity (β-Ram detector) was 98.5% [1.5% of diastereoisomer was detected (retention time: 14.60 min)]. The identity and purity of the material were proven by HPLC analysis by co-injection with the non-labeled reference standard. Mass spectroscopy analysis with in flow injection was performerd. MS (ESI) m/z [ 14 C-M + H] + 410.15, [ 12 C-M + H] + 408.15 The compound shows 89% (by MS measurement) and 87.48% (by gravimetric analysis) of 14 C isotopic enrichment. The specific activity was measured by gravimetric analysis and determined to be 133.35 µCi/mg (4933.95 kBq/mg), 54.6 mCi/mmol. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, the descriptions and examples should not be construed as limiting the scope of the invention. Accordingly, all suitable modifications and equivalents may be considered to fall within the scope of the invention as defined by the claims that follow. The disclosures of all patent and scientific literature cited herein are expressly incorporated in their entirety by reference.